Infections

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Warts

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Bleomycin

Anti-Bacterial Agents

Antibiotics, Antitubercular

Intralesional Bleomycin has been given to palmo plantar warts. Generic name: Bleomycin Dose: 1mg/1ml (0.1%) Frequency: every 2 weekly for 6 weeks.

Cryotherapy has been given to palmo plantar warts. Frequency: every 2 weekly for 6 weeks

Intralesional Bleomycin used for treatment of cutaneous warts.

Bleomycin Injection

Cryotherapy used for comparison of efficacy.

Cryotherapy

Rabia Ghafoor, FCPS

The purpose of the study was to determine the efficacy of intralesional bleomycin in comparison to cryotherapy on participants having cutaneous warts.

This study was conducted in the Department of Dermatology of Jinnah Postgraduate Medical Centre, Karachi from January to June 2021 after receiving approval from the institutional ethical and research committee of hospital.

Sample size was calculated through NCSS software. Total of one fifty four non-admitted patients were assigned two study groups with equal sample size of 77 randomly through lottery method. Those patients aged between 18 to 60 years of either gender with cutaneous warts for \> 1 week to 48 weeks were included after written informed consent. Patients treated previously for warts by any methodology, with history of vascular disease, immunocompromised, hypertension, cardiovascular disorder, pregnancy, lactation and hypersensitivity to lidocaine were excluded.

All demography, clinical history was recorded by a principal investigator on a predesigned Performa , informed written consent was taken before enrolment.

Group A received intralesional bleomycin 0.1% therapy until the lesion blanched. It was prepared manually by diluting 15 mg powder in 5 ml distilled water and then each ml was further diluted by adding 2ml of 2% lignocaine, double the amount taken from the vial, so that concentration became 1mg/1ml (0.1%). Group B patients were treated with liquid nitrogen with the help of a cotton swab wrapped on a wooden stick and was applied firmly with 01 mm extra healthy skin margin until the lesion blanched.

Follow-up was carried out at 02, 04 and 06 weeks. Both the groups were assessed and compared for efficacy after 6 weeks of therapy. SPSS 23 was used for analyzing data.

Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts

There is complete remission of cutaneous warts, assessed clinically

Jinnah Postgraduate Medical Centre

FCPS II Postgraduate Trainee

Bone Density Conservation Agents

Micronutrients

Vitamins

Vitamin D

Cholecalciferol

Trace Elements

Hormones

Calcium

Calcium, Dietary

Vitamin D3

Calciferol

liquid nitrogen In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.

intralesional Vit D3 Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.

In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.

liq nitrogen

Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.

intralesional vitamin D3

A total of 60 female patients (30 patients in each group) with cutaneious warts diagnosed by a consultant dermatologist on physical examination were included in this study.

In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) while patients in Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness in both groups was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.

Comparisom of Liquid Nitrogen and Vitamin D3 in The Treatment of Cutaneous Warts

Comparison of Efficacy of Liquid Nitrogen Versus Vitamin D3 in The Treatment of Cutaneous Warts

For 2nd Article: A total of 60 female patients (30 patients in each group) with cutaneous warts diagnosed by a consultant dermatologist on physical examination were included in this study.

In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) while patients in Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness in both groups was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.Total duration of therapy for each patient will be 9 weeks after "recurrence and remission"

Combined Military Hospital Abbottabad

principal investigator

Anti-Arrhythmia Agents

Cardiotonic Agents

Natriuretic Agents

Digoxin

Furosemide

Diuretics

Sodium Potassium Chloride Symporter Inhibitors

Enzyme Inhibitors

Protective Agents

CLS003

Vehicle topical

J. (Koos) Burggraaf, MD, PhD

A phase 2, randomized, vehicle-controlled, double-blind study to assess the efficacy, safety and pharmacodynamics (PD) of topically applied CLS003 in otherwise healthy patients with cutaneous warts.

A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.

A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Cutaneous Warts

Maruho Co., Ltd.

up to a maximum of four treatments every 21-28 days

laser

Shichao Lu, MD

The purpose of this study is to test the efficacy of laser versus cryotherapy on the treatment of warts

Cutaneous warts were a common skin diseases caused by human papilloma virus (HPV) infection. Although warts may spontaneously resolve, many patients seek for treatment for various reasons. There are many kinds of treatments for cutaneous warts, including salicylic acid, cryotherapy, laser, etc. A recent high quality RCT confirmed that the cure rate of topical salicylic acid and frozen has no difference at six months, but the efficacy of laser versus cryotherapy on the treatment of warts remains unclear. Therefore, we designed a randomized controlled trial to test the efficacy of laser versus cryotherapy on the treatment of warts.

Efficacy of Laser Versus Cryotherapy in the Treatment of Warts

Cryotherapy Versus Laser for the Treatment of Nongenital Cutaneous Warts: A Randomized Controlled Clinical Trial

Warts was considered cured if they was no longer visible and could not be palpated anymore by hand. Assessment of whether or not cured was performed on site by a senior dermatologist

Effective assessment is performed by a senior dermatologist.

A wart was considered recurrence if there are abnormalities or palpated foreign body in the original place.

Cure days was defined as the period from the first treatment until the date of clearance.

including pain, swelling, blisters, blood blisters, bruising, bleeding,scarring, hypopigmentation, hyperpigmentation.

on a scale of 0-10, where 0 is no pain and 10 is extremely painful

on a five-point scale, from 'very satisfied' to 'very satisfied'

take a small amount of cutaneous warts lesions and extract HPV DNA before treatment

Peking University

The 306 Hospital of People's Liberation Army

M.D.

Neoplasms

Wounds and Injuries

Papilloma

Hyperthermia

Fever

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.

Common warts, plantar warts, and condyloma acuminata

Liquid nitrogen crytotherapy at days 1, 15, 30.

As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied

liquid nitrogen

As an experimental arm, for patients with cutaneous warts

controllable infrared bioeffect system

Xinghua Gao

Local hyperthermia at 44℃ can promote some alterations of immulogical indicators. The procedure is convenient in clinic, has high tolerance with less trauma and less pain. Based on domestic and abroad clinical practice, the investigators observed initially that local hyperthermia brought great benefits to cutaneous warts. In comparison with liquid nitrogen, the safety and efficacy of controllable infrared bioeffect system to treat skin disease has been evaluated. This proved it could be used in treatment of skin warts, and clinical trial met the requirements of Standards for quality control of clinical trials on medical devices, and can be used in product registration and declaration.

Mild local Hyperthermia with a certain temperature range has been successfully used in the treatment of some diseases. It has been utilised in the treatment of some neoplasm, fungal and HPV infections. Investigators' study found that local hyperthermia at 44°C could cleared HPV in more than half of the patients with plantar warts. Investigators also note the fact that in patients with multiple lesions, the clearance of the target lesion is commonly followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response to eliminate HPV.So the purpose of the study is to evaluate the safety and efficacy of controllable infrared bioeffect system to treat cutaneous warts. This trial was designed into two groups, one was experimental group (thermal therapy group), the other one was control group (liquid nitrogen cryotherapy group). The ratio of participants was 1:1 in experiment group and control group. The main evaluation indicator was the recovery rate after 4 months of initial treatment.

Infrared Bioeffect System for the Treatment of Cutaneous Warts

Evaluation of Controllable Infrared Bioeffect Effect for the Treatment of Cutaneous Warts After 3 Months: a Multicenter, Randomized, Open Label Controlled Trial

to evaluate the clearance rate in different treatment groups 3 months after treatment

to evaluate the recovery rate of target lession in different treatment groups 3 months after treatment

to evaluate the recovery rate of non-target lession in different treatment groups 3 months after treatment

to evaluate the score of VAS (0 score represents no pain; 10 score represents sharp pain) in different treatment groups 3 months after treatment

to evaluate the clearance rate of virus in different treatment groups 3 months after treatment

First Hospital of China Medical University

Professor

Digestive System Diseases

Rare Diseases

Hepatitis A

Hepatitis

Hepatitis B

Liver Diseases

Gastrointestinal Diseases

Blood-Borne Infections

Hepadnaviridae Infections

Hepatitis, Viral, Human

Herpes Simiae (B Virus)

Hypoglycemic Agents

Vaccines

Insulin

Insulin, Globin Zinc

Vitamin A

Retinol palmitate

Retinol

Group 1: will include 22 patients with multiple plane or genital warts. They will be treated by intralesional injection of HBV vaccine at a dose of (0.3 ml) into the largest wart by an insulin syringe every 2-weeks until complete clearance or for a maximum of 5 sessions.

Group 2: will include 22 patients with multiple plane or genital warts. They will be treated by intralesional injection of HBV vaccine at a dose of (0.5 ml) into the largest wart by an insulin syringe every 2-weeks until complete clearance or for a maximum of 5 sessions.

Group 3: will include 22 patients with multiple plane or genital warts. They will be treated by intramuscular injection of HBV vaccine at a dose of (0.5 ml)in patients who are 18 years or younger and (1ml)in patients older than 18 years in the deltoid muscle using a 25-gauge syringe every month until complete clearance or for a maximum of 3 months.

Hepatitis B Virus Vaccine(HBV)

Maria Awny, Master

Sahar Abd-Elmoez, Professor

Aim of the work:

1. Evaluate efficacy and safety of Intralesional HBV vaccine injection as a treatment of plane and genital warts.
2. Evaluate efficacy and safety of Intramuscular HBV vaccine injection as a treatment of plane and genital warts.
3. Compare the efficacy of different doses(0.3ml vs 0.5ml )of intralesional HBV vaccine injection for treatment of plane and genital warts.
4. Compare the efficacy of intralesional HBV vaccine injection vs Intramuscular HBV vaccine injection in treatment of plane and genital warts.

INTRODUCTION:

Warts are common, benign and epithelial proliferations and growths affecting the skin and/or the mucosa caused by human papilloma virus (HPV) which is a double stranded DNA virus with a worldwide distribution.

There are approximately 218 types of HPV identified as causing infections in humans .

Infection occurs predominantly via direct contact, although skin lesions can be transmitted indirectly, via contaminated surfaces, Abrations and microtraumas expose the basal layer keratinocytes and facilitate contagion .

The clinical manifestations of HPV-related diseases vary depending upon the HPV type and the site of inoculation .Extragenital cutaneous warts can present as common warts, plane warts, plantar warts .HPV infection is one of the most common sexually transmitted infections with the most common manifestation of HPV in the genital area is anogenital warts or condylomata acuminate . Infections due to these viruses may result in a wide spectrum of clinical manifestations in the skin and mucosa.

Although cutaneous warts are mostly benign with spontaneous resolution after months or years in healthy patients. Nonetheless, they can grow, cause discomfort or embarrassment to patients, or persist for months or years, increasing viral transmission between individuals. Also, anogenital warts caused by high risk strains possess an oncogenic potential .

Several therapeutic modalities have been used to treat HPV infections. The choice of treatment should take into account factors such as age, location, number and size of the lesions, clinical subtype and the patient's immunological status.

Available treatment modalities include physical destruction (e.g., cryotherapy, electrosurgery, ablative laser, or surgical removal), chemical destruction (e.g., salicylic acid or trichloroacetic acid), and anti-proliferative agents (e.g., podophyllin, 5-fluorouracil or bleomycin). Unfortunately, no treatment has yet shown 100% effectiveness as a cure. Furthermore these modalities have side-effects (e.g. pain, erythema, burning sensation and scarring) .Classical treatment lines are associated with high recurrence rates as they are limited to local application and do not act systemically .So, there is a need for therapies with a greater efficacy and minimal side-effects .

Immunotherapeutic agents act by enhancing the host cell-mediated immunity that helps to eliminate the virus rather than simply destroying visible skin lesions and have recently received increasing attention for the treatment of warts because of their non-destructive action, high safety profiles, promising results, and low recurrence rates. Contact immunotherapy using contact sensitizers (diphenylcyclopropenone or dinitrochlorobenzene), topical imiquimod, oral cimetidine or intralesional immunotherapy has been attempted as viable immunotherapeutic options for treatment of warts.

Intralesional immunotherapy has been assessed as an alternative therapeutic approach, particularly for cases of recalcitrant or multiple warts, since it may facilitate the clearance of not only the injected wart but also surrounding non-injected warts. Various immunotherapeutic agents including skin test antigens (mumps, Candida, and Trichophyton); the combined measles, mumps, and rubella vaccine(MMR); the tuberculin purified protein derivative(PPD); Mycobacterium w vaccine; and bacillus Calmette-Guérin(BCG) vaccine have been assessed.

Hepatitis B virus (HBV) vaccine is a highly safe and effective DNA vaccine against HBV infection that is recommended for all infants at birth and for children. It is also recommended for adults at high risk for infection because of their jobs, lifestyle, or living situations. It is relatively cheap, easy to produce, and extremely stable. Besides, HBV vaccination is associated with the stimulation, not only of humoral immunity that induces antibody production against Hepatitis B surface antigen (HBsAg), but also of cell-mediated immunity, particularly T helper1 Th1 cytokines such as interferon γ( IFN-γ )and interleukin2(IL-2). Furthermore, HBV vaccine has the advantage of being a non-live vaccine that can be used safely in immunocompromised patients in contrast to the live vaccines such as measles, mumps, and rubella (MMR), Bacillus Calmette-Guerin (BCG) that may pose high risks to the immunocompromised patients .

Only two researches studied the efficacy of intralesional HBV vaccine injection in treatment of multiple common warts. Both studies revealed low success rate (20.7% and 23.3% respectively) of intralesional HBV vaccine at a dose of 0.2ml injected into the largest wart in biweekly sessions for a maximum of 5 sessions. It Worth mentioning that one the two studies also examined the efficacy of intramuscular injection of HBV vaccine at higher doses (0.5 ml and 1 ml/ injection) for 3 injections and reported a complete clearance of common warts in 50% of the patients, which was statistically significant higher than percentage of those patients who achieved complete clearance after treatment with intralesional injection of HBV vaccine using 0.2 ml/session for five sessions. Whether this significant difference is related to the different treatment dosage or to the different administration routes is still to be unraveled by further studies.

Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts

size of cutaneous warts in millimeters will be measured every visit

number of cutaneous warts will be measured every visit

Assiut University

Principal Investigator

CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.

In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.

In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed.

Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.

Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).

The treatment groups are:

* CyPep-1 topical formulation 1% (w/w)
* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.

Cypep-1

This Phase 1 study is intended to explore the safety, tolerability, pharmacodynamics and efficacy of topical CyPep-1 as a potential treatment for HPV-associated conditions. Since this is a first-on-human study of a topical formulation, the first subjects will be monitored more frequently in order to establish the safety profile. Because clinical outcomes (i.e. reduction/clearance of the lesion) often require lengthy treatment / observation periods, the study design will primarily utilize clinical measurements of wart dimensions, along with HPV viral load as a biomarker of anti-viral effect.

This study has a phase 1, randomized, vehicle-controlled, double-blind, single center design to explore the safety, tolerability and pharmacodynamics (PD) of topically applied CyPep-1 in otherwise healthy patients with cutaneous warts.

The study will entail two parts. Part 1 will follow a target area of 5x5 cm healthy skin to study tolerability and safety of the formulation. During this study part also a maximum of 3 common warts, preferably at the dorsal or palmar side of the hand / finger(s), will be treated. Several assessments will be done to determine pharmacodynamics and to explore possible efficacy after a treatment period of 1 week.

Part 2 will evaluate the pharmacodynamics and efficacy of CyPep-1 after a treatment period of 4 weeks. Study part 2 will commence after an interim analysis, e.g. a blind data review, of study part 1 has been conducted.

Randomized, placebo-controlled, double-blind phase I study

This study will be performed in a double-blind fashion. The investigator, study staff, subjects, sponsor, and monitor will remain blinded to the treatment until study closure. The investigational drug and its matching placebo are indistinguishable and will be packaged in the same way.

CyPep-1 in Cutaneous Warts

A Randomized, Placebo-controlled, Double-blind Phase I Study to Explore Safety, Tolerability and Pharmacodynamics of CyPep-1 in Subjects With Cutaneous Warts

Blood samples will be collected for measurement of CyPep-1 plasma concentration.

Part 1:

Daily during treatment period and at Day 14.

Part 2:

At Day 28 (End of Trial)

Part 1:

Heart rate (number of pulses/min) will be measured during the time points described below.

Blood pressure (mmHg) will be measured during the time points described below.

Body temperature (degrees Celsius) will be measured during the time points described below.

AEs and AEs will be recorded during all visits.

Wart size (in mm) will be measured during the time points described below.

Part 1:

Swabs will be obtained every 48h during treatment period and at the FU visits.

Part 2:

Swabs will be obtained at all study visits.

Centre for Human Drug Research, Netherlands

Dermatologic Agents

Other Dietary Supplements

Salicylic Acid

Eugenol

100% AV2 (v/v) - 17% SA (w/v) treatment one drop daily and 10% AV2 (v/v) spray one puff weekly

100% d-carvone (v/v) - 17% SA (w/v) treatment one drop daily and 10% d-carvone (v/v) spray one puff weekly

AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.

AV2-SA2

Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.

Cutaneous warts comprise an extremely common condition caused by infection with the human papillomavirus (HPV). Although most verrucae will disappear spontaneously, many patients do seek treatment. Current wart treatments do not target the cause of the lesion directly, resulting in variable treatment efficacies and high wart recurrence rates. AV2 is a broad-spectrum antiviral drug, that is capable of deactivating HPV. It is however not able to destruct the already infected cells, which raises the need for an additional ablative treatment i.e. salicylic acid (SA). Implementation of AV2-Salicylic acid (AV2-SA) combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment. The primary aim of this study is to assess the efficacy of AV2-SA treatment versus standard SA treatment, by comparing cure and recurrence rates of cutaneous warts between the two treatment groups (at 12 weeks and six months after randomization). The second aim is to assess the safety and tolerability of AV2-SA therapy. The third aim is to identify subgroups of cutaneous warts that have favorable response to treatment, by comparing cure rates in an HPV genotype-specific manner. This randomized controlled trial will enroll 260 participants with cutaneous warts who will either receive the AV2-SA combination therapy or SA control treatment. Real time monitoring will be possible by daily photographs sent via WhatsApp TM (a messaging application) as well as online follow-up questionnaires administered on several occasions. HPV genotyping will be performed on swab self-samples.

A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts

To assess the efficacy of AV2-SA treatment versus standard SA treatment by comparing cure rates of the index warts between the two treatment groups at 12 weeks after enrollment.

To assess the efficacy of AV2-SA treatment versus standard SA treatment by comparing recurrence rates of the index warts between the two treatment groups at 6 months after enrollment.

The safety of both treatments will be assessed by monthly questionnaires actively asking the participants if they experienced any pain or other treatment-related adverse events. Pain will be measured with a scale of 1 to 4, with score 1 representing no pain at all and score 4 extreme pain.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts	NCT05023408	Cutaneous Warts	Bleomycin Injec... Cryotherapy	18 Years - 60 Years	Jinnah Postgraduate Medical Centre
Comparisom of Liquid Nitrogen and Vitamin D3 in The Treatment of Cutaneous Warts	NCT05739786	Cutaneous Warts	liq nitrogen intralesional v...	18 Years - 60 Years	Combined Military Hospital Abbottabad
A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.	NCT02333643	Cutaneous Warts	CLS003 Furosemide Digoxin Vehicle topical	18 Years - 65 Years	Maruho Co., Ltd.
Efficacy of Laser Versus Cryotherapy in the Treatment of Warts	NCT01808443	Warts	Cryotherapy laser	18 Years -	The 306 Hospital of People's Liberation Army
A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.	NCT02333643	Cutaneous Warts	CLS003 Furosemide Digoxin Vehicle topical	18 Years - 65 Years	Maruho Co., Ltd.
Infrared Bioeffect System for the Treatment of Cutaneous Warts	NCT03734003	Cutaneous Warts Human Papilloma...	liquid nitrogen controllable in...	18 Years - 70 Years	First Hospital of China Medical University
Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts	NCT05902624	Cutaneous Warts	Hepatitis B Vir...	10 Years -	Assiut University
CyPep-1 in Cutaneous Warts	NCT03846648	Cutaneous Warts	Cypep-1	18 Years - 65 Years	Centre for Human Drug Research, Netherlands
Comparisom of Liquid Nitrogen and Vitamin D3 in The Treatment of Cutaneous Warts	NCT05739786	Cutaneous Warts	liq nitrogen intralesional v...	18 Years - 60 Years	Combined Military Hospital Abbottabad
A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts	NCT05862441	Cutaneous Warts	AV2-SA2 SA	12 Years -	Universiteit Antwerpen
CyPep-1 in Cutaneous Warts	NCT03846648	Cutaneous Warts	Cypep-1	18 Years - 65 Years	Centre for Human Drug Research, Netherlands
Efficacy of Laser Versus Cryotherapy in the Treatment of Warts	NCT01808443	Warts	Cryotherapy laser	18 Years -	The 306 Hospital of People's Liberation Army

Spots Global Cancer Trial Database for cutaneous warts